← Oncology Approval Tracker

FDA DECISION ·

Keytruda + Lenvima

pembrolizumab with lenvatinib · Merck / Eisai

FDA approvalNew or expanded indicationRenal cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line treatment of adults with advanced renal cell carcinoma.

LAMPGEN ANALYSIS

Why it matters

The combination adds an immune checkpoint inhibitor and VEGF-targeted oral therapy as a first-line option.

What research teams should watch

Track infusion visits and oral dose interruptions together and reconcile attribution of hypertension and other events.

PRIMARY RECORDS

Sources